Current Evidence for Stereotactic Body Radiotherapy in Lung Metastases

Overview

Journal Curr Oncol

Publisher MDPI

Specialty Oncology

Date 2021 Jul 21

PMID 34287274

Citations 6

Authors

Enrique Gutierrez

Irving Sanchez

Omar Diaz

Adrian Valles

Ricardo Balderrama

Jesus Fuentes

Brenda Lara

Cipatli Olimon

Victor Ruiz

Jose Rodriguez

Luis H Bayardo

Matthew Chan

Conrad J Villafuerte

Jerusha Padayachee

Alexander Sun

Affiliations

Soon will be listed here.

Abstract

Lung metastases are the second most common malignant neoplasms of the lung. It is estimated that 20-54% of cancer patients have lung metastases at some point during their disease course, and at least 50% of cancer-related deaths occur at this stage. Lung metastases are widely accepted to be oligometastatic when five lesions or less occur separately in up to three organs. Stereotactic body radiation therapy (SBRT) is a noninvasive, safe, and effective treatment for metastatic lung disease in carefully selected patients. There is no current consensus on the ideal dose and fractionation for SBRT in lung metastases, and it is the subject of study in ongoing clinical trials, which examines different locations in the lung (central and peripheral). This review discusses current indications, fractionations, challenges, and technical requirements for lung SBRT.

Citing Articles

Recent Advances and Current Challenges in Stereotactic Body Radiotherapy for Ultra-Central Lung Tumors.

Salvestrini V, Lastrucci A, Banini M, Loi M, Carnevale M, Olmetto E Cancers (Basel). 2025; 16(24.

PMID: 39766035 PMC: 11674056. DOI: 10.3390/cancers16244135.

Thrombopoietin mimetic reduces mouse lung inflammation and fibrosis after radiation by attenuating activated endothelial phenotypes.

English J, Dhanikonda S, Tanaka K, Koba W, Eichenbaum G, Yang W JCI Insight. 2024; 9(21).

PMID: 39513364 PMC: 11601560. DOI: 10.1172/jci.insight.181330.

Radioresistant Pulmonary Oligometastatic and Oligoprogressive Lesions From Nonlung Primaries: Impact of Histology and Dose-Fractionation on Local Control After Radiation Therapy.

Verma N, Laird J, Moore N, Hayman T, Housri N, Peters G Adv Radiat Oncol. 2024; 9(6):101500.

PMID: 38699671 PMC: 11063223. DOI: 10.1016/j.adro.2024.101500.

Radiomics in Lung Metastases: A Systematic Review.

Gabelloni M, Faggioni L, Fusco R, Simonetti I, De Muzio F, Giacobbe G J Pers Med. 2023; 13(2).

PMID: 36836460 PMC: 9967749. DOI: 10.3390/jpm13020225.

Implementation of advanced radiotherapy techniques: stereotactic body radiotherapy (SBRT) for oligometastatic patients with lung metastasis - a single institution experience.

Pop D, Hopirtean C, Coser F, Dan F, Zah T, Fekete Z Med Pharm Rep. 2022; 95(4):410-417.

PMID: 36506614 PMC: 9694750. DOI: 10.15386/mpr-2362.

References

Salama J, Kirkpatrick J, Yin F . Stereotactic body radiotherapy treatment of extracranial metastases. Nat Rev Clin Oncol. 2012; 9(11):654-65. DOI: 10.1038/nrclinonc.2012.166. View

Kirkpatrick J, Meyer J, Marks L . The linear-quadratic model is inappropriate to model high dose per fraction effects in radiosurgery. Semin Radiat Oncol. 2008; 18(4):240-3. DOI: 10.1016/j.semradonc.2008.04.005. View

Popper H . Progression and metastasis of lung cancer. Cancer Metastasis Rev. 2016; 35(1):75-91. PMC: 4821869. DOI: 10.1007/s10555-016-9618-0. View

Wegner R, Abel S, Hasan S, Schumacher L, Colonias A . Stereotactic Body Radiotherapy (SBRT) for Oligometastatic Lung Nodules: A Single Institution Series. Front Oncol. 2019; 9:334. PMC: 6514183. DOI: 10.3389/fonc.2019.00334. View

Cheung P . Stereotactic body radiotherapy for oligoprogressive cancer. Br J Radiol. 2016; 89(1066):20160251. PMC: 5124800. DOI: 10.1259/bjr.20160251. View

Yamamoto T, Niibe Y, Matsumoto Y, Dekura Y, Oh R, Yamashita H . Stereotactic Body Radiotherapy for Pulmonary Oligometastases from Esophageal Cancer: Results and Prognostic Factors. Anticancer Res. 2020; 40(4):2065-2072. DOI: 10.21873/anticanres.14164. View

Kirkbride P, Cooper T . Stereotactic body radiotherapy. Guidelines for commissioners, providers and clinicians: a national report. Clin Oncol (R Coll Radiol). 2011; 23(3):163-4. DOI: 10.1016/j.clon.2011.01.155. View

Roman A, Perez-Rozos A, Otero A, Jodar C, Garcia-Rios I, Lupianez-Perez Y . Efficacy and safety of a simplified SBRT regimen for central and peripheral lung tumours. Clin Transl Oncol. 2019; 22(1):144-150. DOI: 10.1007/s12094-019-02119-6. View

Grills I, Hugo G, Kestin L, Galerani A, Chao K, Wloch J . Image-guided radiotherapy via daily online cone-beam CT substantially reduces margin requirements for stereotactic lung radiotherapy. Int J Radiat Oncol Biol Phys. 2007; 70(4):1045-56. DOI: 10.1016/j.ijrobp.2007.07.2352. View

10.

Purdie T, Bissonnette J, Franks K, Bezjak A, Payne D, Sie F . Cone-beam computed tomography for on-line image guidance of lung stereotactic radiotherapy: localization, verification, and intrafraction tumor position. Int J Radiat Oncol Biol Phys. 2007; 68(1):243-52. DOI: 10.1016/j.ijrobp.2006.12.022. View

11.

Brown J, Carlson D, Brenner D . The tumor radiobiology of SRS and SBRT: are more than the 5 Rs involved?. Int J Radiat Oncol Biol Phys. 2014; 88(2):254-62. PMC: 3893711. DOI: 10.1016/j.ijrobp.2013.07.022. View

12.

Ricardi U, Badellino S, Filippi A . What do radiation oncologists require for future advancements in lung SBRT?. Phys Med. 2016; 44:150-156. DOI: 10.1016/j.ejmp.2016.11.114. View

13.

Karam S, Bhatia S . The radiobiological targets of SBRT: tumor cells or endothelial cells?. Ann Transl Med. 2015; 3(19):290. PMC: 4671867. DOI: 10.3978/j.issn.2305-5839.2015.09.17. View

14.

Videtic G, Donington J, Giuliani M, Heinzerling J, Karas T, Kelsey C . Stereotactic body radiation therapy for early-stage non-small cell lung cancer: Executive Summary of an ASTRO Evidence-Based Guideline. Pract Radiat Oncol. 2017; 7(5):295-301. DOI: 10.1016/j.prro.2017.04.014. View

15.

Goldstein J, Lawrence Y, Appel S, Landau E, Ben-David M, Rabin T . Continuous Positive Airway Pressure for Motion Management in Stereotactic Body Radiation Therapy to the Lung: A Controlled Pilot Study. Int J Radiat Oncol Biol Phys. 2015; 93(2):391-9. DOI: 10.1016/j.ijrobp.2015.06.011. View

16.

Pastorino U, Buyse M, Friedel G, Ginsberg R, Girard P, Goldstraw P . Long-term results of lung metastasectomy: prognostic analyses based on 5206 cases. J Thorac Cardiovasc Surg. 1997; 113(1):37-49. DOI: 10.1016/s0022-5223(97)70397-0. View

17.

Kjellsson Lindblom E, Hui S, Brooks J, Dasu A, Kujawski M, Toma-Dasu I . Radiation-induced Vascular Damage and the Impact on the Treatment Outcome of Stereotactic Body Radiotherapy. Anticancer Res. 2019; 39(6):2721-2727. PMC: 8881796. DOI: 10.21873/anticanres.13398. View

18.

Budczies J, von Winterfeld M, Klauschen F, Bockmayr M, Lennerz J, Denkert C . The landscape of metastatic progression patterns across major human cancers. Oncotarget. 2014; 6(1):570-83. PMC: 4381616. DOI: 10.18632/oncotarget.2677. View

19.

Fuks Z, Kolesnick R . Engaging the vascular component of the tumor response. Cancer Cell. 2005; 8(2):89-91. DOI: 10.1016/j.ccr.2005.07.014. View

20.

Lewis S, Porceddu S, Nakamura N, Palma D, Lo S, Hoskin P . Definitive Stereotactic Body Radiotherapy (SBRT) for Extracranial Oligometastases: An International Survey of >1000 Radiation Oncologists. Am J Clin Oncol. 2015; 40(4):418-422. DOI: 10.1097/COC.0000000000000169. View